NASDAQ: STAA · Medical Instruments & Supplies
STAAR Surgical (STAA) fair value and price range
As of 28 Sep 2026, Faircurve's model values STAAR Surgical (STAA) at $20.55 a share. The stock last closed at $22.47, which puts the model's fair value 8.5% below the price. The model grades the evidence behind this valuation as low, so no verdict is shown. The grade looks at how complete the inputs are, how many comparable companies there are and how closely they agree, and how wide the range of outcomes is. It does not say how likely the fair value is to be right.
Revalued . Price is the close of 2 Oct 2026. STAAR Surgical Company.
Faircurve Insights · 28 Sep 2026
STAAR Surgical Company, along with its subsidiaries, specialises in ophthalmological solutions. It focuses on the design, development, manufacturing, and commercialisation of implantable lenses for vision correction, complete with sophisticated delivery.
Faircurve's model valued STAAR Surgical Company on 28 Sep 2026. The model's fair value was $20.55 a share, which is the midpoint of 2,000 simulations. The previous run on 19 Sep 2026 gave $20.86, meaning the fair value moved -1.5%. The calibrated range over 63 trading days was $17.24 to $25.06, built from the fair value since there is no live options data. Ranges built this way held the price 60% of the time at this horizon, calibrated weekly against realised prices (4,327 past valuations, refreshed 26 Sep 2026). The model grades the evidence behind this valuation as low.
The model compares STAAR Surgical Company with LeMaitre Vascular, Inc., BioLife Solutions, Inc., ICU Medical, Inc., and Merit Medical Systems, Inc. The stock's moves around its last 8 earnings reports were: 12 Aug 2026 +1.6%, 13 May 2026 +13.6%, 3 Mar 2026 +0.9%, 5 Nov 2025 +5.3%, 6 Aug 2025 -0.3%, 7 May 2025 +3.0%, 11 Feb 2025 -27.1%, and 30 Oct 2024 -4.3%. The median size, ignoring direction, was 3.6%.
Written from the figures on this page for the 28 Sep 2026 valuation and checked by rule before publishing: every number is one printed here, no forecast, no instruction. The price, the gap and the verdict are the page's own and change daily. Not a recommendation.
What price range does the model give STAA?
The calibrated range for STAA over 63 trading days is $17.24 to $25.06. There is no live options data for this stock, so the range is built from the fair value and calibrated weekly against realised prices (n = 4,327 past valuations, refreshed 26 Sep 2026). Ranges built this way held the price 60% of the time at this horizon.
The model's own simulated range, from the 20th to the 80th percentile of its runs, is $17.02 to $24.87. In 50% of the simulations the fair value came out above the price the model ran on.
How does STAA compare with similar companies?
The companies in medical instruments & supplies closest to STAAR Surgical in market value, each on the same model and the same date.
| Company | Last close | Model fair value | Gap | Model verdict |
|---|---|---|---|---|
| LMAT LeMaitre Vascular, Inc. | $78.96 | $76.10 | -3.6% | Fairly valued |
| BLFS BioLife Solutions, Inc. | $37.30 | $33.70 | -9.7% | Fairly valued |
| XRAY DENTSPLY SIRONA Inc. | $8.67 | $15.20 | +75.3% | Gap wider than 60% |
| EMBC Embecta Corp. | $5.65 | $5.57 | -1.4% | Low evidence grade |
| NVST Envista Holdings Corp | $23.46 | $23.26 | -0.9% | Low evidence grade |
| ICUI ICU Medical, Inc. | $159.38 | $191.03 | +19.9% | Undervalued |
| MMSI Merit Medical Systems, Inc. | $85.37 | $88.67 | +3.9% | Fairly valued |
| TFX Teleflex Incorporated | $124.12 | $125.37 | +1.0% | Low evidence grade |
All medical instruments & supplies stocks ranked by gap to fair value
When does STAA report earnings, and how has the stock reacted?
STAAR Surgical's next earnings report is scheduled for 4 Nov 2026. Companies can move their dates.
How STAA moved around its last 8 earnings reports
Each move runs from the last close before the report to the first close after it, so it covers companies that report before the open and after the close. The median size across these 8 reports, ignoring direction, was 3.6%.
| Report date | Two session move |
|---|---|
| 12 Aug 2026 | +1.6% |
| 13 May 2026 | +13.6% |
| 3 Mar 2026 | +0.9% |
| 5 Nov 2025 | +5.3% |
| 6 Aug 2025 | -0.3% |
| 7 May 2025 | +3.0% |
| 11 Feb 2025 | -27.1% |
| 30 Oct 2024 | -4.3% |
STAAR Surgical at a glance
STAAR Surgical Company, along with its subsidiaries, specializes in ophthalmological solutions, focusing on the design, development, manufacturing, and commercialization of implantable lenses for vision correction, complete with the sophisticated delivery.
- Market value
- $1.0B
- Sector
- Healthcare
- Industry
- Medical Instruments & Supplies
- Revenue expected, next twelve months
- $356M
- Consensus revenue growth, next fiscal year
- +39.8%
- Analysts with estimates
- 7
- Beta to the US market
- 0.38
- First valued by Faircurve
- 11 Jul 2026
How the fair value is worked out: the model prices STAAR Surgical on the value of the whole business, debt included, against the operating profit analysts expect next year (forward EV/EBITDA), runs 2,000 simulations across its inputs and takes the midpoint. The full method is documented here.
What changed in the latest valuation?
On 19 Sep 2026 the model's fair value for STAA was $20.86. As of 28 Sep 2026 it is $20.55, a change of -1.5%. The model revalues every stock it covers each week, and again after an earnings report.
Questions about STAAR Surgical's valuation
Is STAAR Surgical stock undervalued or overvalued?
Faircurve's model puts STAA's fair value at $20.55 a share against a last close of $22.47, as of 28 Sep 2026. The model grades the evidence behind this valuation as low, so no verdict is shown. The grade looks at how complete the inputs are, how many comparable companies there are and how closely they agree, and how wide the range of outcomes is. It does not say how likely the fair value is to be right.
What is STAA's fair value?
$20.55 a share as of 28 Sep 2026, the midpoint of 2,000 simulations. The model's own 20th to 80th percentile range is $17.02 to $24.87.
What price range does the model give STAA?
$17.24 to $25.06 over 63 trading days. Ranges built this way held the price 60% of the time across 4,327 past valuations, refreshed 26 Sep 2026.
When does STAAR Surgical report earnings next?
The next report is scheduled for 4 Nov 2026. Companies can move their dates.
How much has STAA moved on past earnings reports?
Across its last 8 reports the median two session move was 3.6%, ignoring direction. The largest was -27.1% around the report of 11 Feb 2025.
How confident is the model in this valuation?
The model's evidence grade for STAA is low. The grade looks at how complete the inputs are, how many comparable companies there are and how closely they agree, and how wide the range of outcomes is. It is not a probability that the fair value is right, or that the price reaches it.